Gene · 7518
Papers3,098
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 3,098
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Chromatin compartmentalization regulates the response to DNA damage. | Nature | 2023 | 37853125 | PubTator, text mining | PubMed |
| New Facets of DNA Double Strand Break Repair: Radiation Dose as Key Determinant of HR versus c-NHEJ Engagement. | Int J Mol Sci | 2023 | 37834403 | PubTator, text mining | PubMed |
| Identification of alternative splicing associated with clinical features: from pan-cancers to genitourinary tumors. | Front Oncol | 2023 | 37810965 | PubTator, text mining | PubMed |
| Gene expression of non-homologous end-joining pathways in the prognosis of ovarian cancer. | iScience | 2023 | 37810216 | PubTator, text mining | PubMed |
| Double-strand DNA break repair: molecular mechanisms and therapeutic targets. | MedComm (2020) | 2023 | 37808268 | PubTator, text mining | PubMed |
| Human skeletal myopathy myosin mutations disrupt myosin head sequestration. | JCI Insight | 2023 | 37788100 | PubTator, text mining | PubMed |
| Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells. | J Neurooncol | 2023 | 37783879 | PubTator, text mining | PubMed |
| A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177Lutetium-DOTA-octreotate radionuclide therapy. | Theranostics | 2023 | 37771787 | PubTator, text mining | PubMed |
| Targeting DNA Damage Repair and Immune Checkpoint Proteins for Optimizing the Treatment of Endometrial Cancer. | Pharmaceutics | 2023 | 37765210 | PubTator, text mining | PubMed |
| TDP-43 Epigenetic Facets and Their Neurodegenerative Implications. | Int J Mol Sci | 2023 | 37762112 | PubTator, text mining | PubMed |
| RNF126, 168 and CUL1: The Potential Utilization of Multi-Functional E3 Ubiquitin Ligases in Genome Maintenance for Cancer Therapy. | Biomedicines | 2023 | 37760968 | PubTator, text mining | PubMed |
| Dose-Dependent Shift in Relative Contribution of Homologous Recombination to DNA Repair after Low-LET Ionizing Radiation Exposure: Empirical Evidence and Numerical Simulation. | Curr Issues Mol Biol | 2023 | 37754249 | PubTator, text mining | PubMed |
| A novel risk model of three gefitinib-related genes FBP1, SBK1 and AURKA is related to the immune microenvironment and is predicting prognosis of lung adenocarcinoma patients. | Aging (Albany NY) | 2023 | 37737707 | PubTator, text mining | PubMed |
| Genome-wide analysis of DNA-PK-bound MRN cleavage products supports a sequential model of DSB repair pathway choice. | Nat Commun | 2023 | 37717054 | PubTator, text mining | PubMed |
| Aflatoxin B1-DNA adducts modify the effects of post-operative adjuvant transarterial chemoembolization improving hepatocellular carcinoma prognosis. | Explor Target Antitumor Ther | 2023 | 37711588 | PubTator, text mining | PubMed |
| Activation of the DNA damage response pathway in the infected gastric tissue with Helicobacter pylori: a case-control study. | J Infect Dev Ctries | 2023 | 37699095 | PubTator, text mining | PubMed |
| Extracellular calcium functions as a molecular glue for transmembrane helices to activate the scramblase Xkr4. | Nat Commun | 2023 | 37696806 | PubTator, text mining | PubMed |
| DNA damage and repair dependencies of ionising radiation modalities. | Biosci Rep | 2023 | 37695845 | PubTator, text mining | PubMed |
| X-ray cross-complementing family: the bridge linking DNA damage repair and cancer. | J Transl Med | 2023 | 37679817 | PubTator, text mining | PubMed |
| Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor. | Cancer Res Commun | 2023 | 37663435 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7518/papers?page=8